
 **Michigan Liver Cancer Consortium 4/30/24 | 04/30/2024 5:30 PM Eddie Merlot's**

An interactive program to learn key updates in the management of liver carcinoma in 2024, and engage in active case discussions with local experts in the field. This is a multi-disciplinary program for physicians, APPs, nursing, and learners of all levels. Experts in Hepatobiliary Surgery, Medical Oncology, Hepatology, Interventional Radiology, Diagnostic Radiology, and Radiation Oncology from around the state will interact to discuss current management strategies and challenges that clinicians face in the care of patients with liver cancer.

**Program Goal**

1 To understand the latest data and approved therapies for systemic therapy in hepatocellular carcinoma management.

2 To learn about locoregional therapies for treatment of liver cancer, and strategies to choose specific therapies.

3 To discuss when to consider combination therapy utilizing liver-directed treatment along with systemic therapy for improved outcomes.

4 To collaborate with colleagues at other local institutions and learn about available options for treatment of liver cancer and clinical trial options for patients.

5 To understand why histotripsy may be a future option and which patients should be considered for this new therapy.

6 To review the patient best suited for surgical resection and/or liver transplant for liver cancer.

7 To discuss current approaches to using radiation therapy for patients with hepatocellular carcinoma.

**Target Audience** Hematology / Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Nik Kolicaj, MD | Faculty | Nothing to disclose - 08/30/2023 |
| Reena Salgia, MD, FAASLD | Course Director, Faculty | Advisor-Eisai (Relationship has ended)|Advisor-Exelixis (Relationship has ended) - 02/16/2024 |
| Christina Miller, BS | CME Specialist | Nothing to disclose - 12/21/2023 |
| Parag Parikh, MD | Faculty | Speakers Bureau-Viewray (Relationship has ended)|Grant or research support-Viewray (Relationship has ended) - 01/23/2024 |
| John Fallucca, MD | Faculty | Nothing to disclose - 02/26/2024 |
| Marwan Abouljoud, MD | Faculty | Advisor-TransMedics - 02/16/2024 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/20/2024 |
| Tami O'connor | Activity Coordinator | Nothing to disclose - 05/03/2023 |
| Sreenivasa Chandana, MD | Faculty | Grant or research support-AbbVie|Grant or research support-Adcentrx Therapeutics|Grant or research support-Amgen|Grant or research support-Astrazeneca|Grant or research support-Cardiff Oncology |Grant or research support-Dicephera |Grant or research support-Elevation Oncology|Grant or research support-Exact Sciences|Grant or research support-Genentech/Roche|Grant or research support-IDEAYA Biosciences|Grant or research support-IGM Biosciences|Grant or research support-Janssen|Grant or research support-Incyte|Grant or research support-Ipsen|Grant or research support-Merck|Grant or research support-Mirati |Grant or research support-Novocure|Speakers Bureau-Natera|Grant or research support-Qualigen Therapeutics |Grant or research support-Zyme Works - 01/23/2024 |
| Mohammed Najeeb Al Hallak, MD | Faculty | Speakers Bureau-Astrazeneca|Speakers Bureau-Guardant Health|Speakers Bureau-Ipsen|Speakers Bureau-Seagen - 01/23/2024 |
| Neehar Parikh, MD | Faculty | Consulting Fee-Astrazeneca|Consulting Fee-Exact Sciences|Advisor-Genentech (Relationship has ended)|Consulting Fee-Exelixis|Advisor-Eisai (Relationship has ended) - 02/19/2024 |
| Mishal Mendiratta-Lala, MD | Faculty | Nothing to disclose - 04/28/2024 |
| Kyle Cuneo, MD | Faculty | Nothing to disclose - 03/12/2024 |
| Chris Sonnenday, MD, FACS, FAASLD | Faculty | Nothing to disclose - 03/14/2024 |
| Jeffrey Critchfield, MD, FSIR | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Trisalus|Independent Contractor (included contracted research)-Boston Scientific|Independent Contractor (included contracted research)-WCG - 03/17/2024 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 2.25 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.